Caplin Point Laboratories (NSE:CAPLIPOINT) Total Equity: ₹36,308 Mil (As of Mar. 2026)


NSE:CAPLIPOINT Caplin Point Laboratories Ltd NSE:CAPLIPOINT
92 GF Score
Price ₹2,538.20
GF Value ₹2,078.80
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Caplin Point Laboratories Total Equity?

Caplin Point Laboratories NSE:CAPLIPOINT -1.01% 92 Total Equity is ₹36,308 Mil as of Mar. 2026. GuruFocus rates NSE:CAPLIPOINT with a GF Score™ of 92/100 and a GF Value™ of ₹2,078.80 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Caplin Point Laboratories's total equity for the quarter that ended in Mar. 2026 was ₹36,308 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Caplin Point Laboratories Total Equity Historical Data

* Premium members only.

The historical data trend for Caplin Point Laboratories's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Caplin Point Laboratories Total Equity Chart

Caplin Point Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15,098.80 19,072.70 23,468.30 28,863.90 36,308.00

Caplin Point Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28,863.90 0.00 31,989.90 0.00 36,308.00
NSE:CAPLIPOINT
92GF Score
Caplin Point Laboratories Ltd NSE:CAPLIPOINT
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Caplin Point Laboratories Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Caplin Point Laboratories's Total Equity for the fiscal year that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=40454.8-4146.8
=36,308

Caplin Point Laboratories's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=40454.8-4146.8
=36,308

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of ₹36,308 Mil mean?
Caplin Point Laboratories (NSE:CAPLIPOINT) has a Total Equity of ₹36,308 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Caplin Point Laboratories and its competitors.
Is Caplin Point Laboratories' Total Equity too high?
Caplin Point Laboratories' current Total Equity is ₹36,308 Mil. Overall, Caplin Point Laboratories has a GF Score™ of 92/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Caplin Point Laboratories' Total Equity compare to ZTS and UTHR?
Caplin Point Laboratories' Total Equity of ₹36,308 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Caplin Point Laboratories and its competitors. Caplin Point Laboratories's current Total Equity is ₹36,308 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caplin Point Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Caplin Point Laboratories (NSE:CAPLIPOINT) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,078.80, compared to a current price of ₹2,538.20 — trading 22.1% above its estimated fair value. The current Total Equity is ₹36,308 Mil. Caplin Point Laboratories' overall GF Score™ is 92/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Caplin Point Laboratories (NSE:CAPLIPOINT), the current Total Equity is ₹36,308 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Caplin Point Laboratories (NSE:CAPLIPOINT) Overvalued in 2026?

Based on GuruFocus' analysis, Caplin Point Laboratories stock appears to be overvalued. The current stock price of ₹2,538.20 is trading 22.1% above its estimated GF Value™ of ₹2,078.80. GuruFocus considers Caplin Point Laboratories to be Modestly Overvalued.

Key valuation signals for NSE:CAPLIPOINT:

  • Total Equity: ₹36,308 Mil
  • GF Value™: ₹2,078.80 vs. price of ₹2,538.20 (22.1% above fair value)
  • GF Score™: 92/100 with 5 warning signs

No single metric tells the full story. See the NSE:CAPLIPOINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Caplin Point Laboratories Business Description

Other Exchanges 524742:India
Address Ashvich Tower, Developed Plots Industrial Estate, No. 3, 3rd Floor, Perungudi, Chennai, TN, IND, 600 096
Caplin Point Laboratories Ltd is an India-based pharmaceutical company. It is engaged in the manufacturing and marketing of pharmaceutical products. The company's key products include tablets, capsules, injections (liquid and lyophilized, prefilled syringes), ophthalmic solutions, liquid orals, soft gel capsules, ointments, creams, gels, powders for injections, suppositories, ovules, pre-mix bag formulations, inhalers, sprays, and IV infusions. It also provides pharmaceutical formulations in specialized injectable dosage forms and Ophthalmic drops.
92GF Score

Get the complete analysis for NSE:CAPLIPOINT

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,538.20
Price
₹2,078.80
GF Value